People with Severe Disabilities are at a Disadvantage for Early Detection and Treatment of Lung Cancer
Lung cancer patients with severe disabilities underwent less staging work-up and treatment and had slightly higher overall mortality compared to people with no disability.
Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs).
Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance.
Significant disparities in the quality of end-of-life lung cancer care were found among racial-ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end-of-life as compared with non-Hispanic whites.
Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival (OS) when treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.
Lung Cancer Clinical Trial Eligibility Criteria and Requirements Have Increased in Number and Complexity
Eligibility criteria continue to increase in number and complexity for lung cancer clinical trials.